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treatment groups using a table of random numbers. The randomisation protocol was stratified according to study site, and a sealed envelope system was established in each hospital. Patients were followed up for 48 hours after surgery. No patients were lost to follow-up.
Analysis of effectiveness
The analysis of the clinical study was based on intention to treat. Primary health outcomes included pain assessment (using a visual analogue scale and the McGill Pain Questionnaire), respiratory rate, degree of sedation, use of medication, post-operative recovery time, side effects, and patient satisfaction. No significant differences were found between the two treatment groups in terms of any of the patients' demographic or clinical characteristics.
Effectiveness results
No significant differences were observed in terms of pain levels or post-operative recovery time. Time to sit in a chair without assistance was significantly longer in PCA patients: 43 hours (+/-16) compared with 35 (+/-11), (p=0.003). Time to resumption of a solid diet was 49 (+/-13) hours for HD hospital and 83 (+/-28) hours for RV hospital, (p<0.0001). Time to return of bowel function after surgery was 77 (+/-30) hours for HD hospital and 57 (+/-16) hours for RV hospital, (p<0.004). Mean visual analogue ratings for the overall efficacy of the analgesic treatment were 8.7 (+/-1.5) for the PCA group and 8.8 (+/-1.5) for the intramuscular group, (p=0.79). Patients in the intramuscular group received more morphine than the PCA patients: 132 (+/-37) mg versus 93 (+/-50) mg, (p<0.0001). None of PCA patients required rescue medication compared with 30% in the intramuscular group. Dose adjustments were necessary more frequently in the intramuscular group (63%) than in the PCA group (15%), (p<0.0001). Analgesic treatment for more than 10% of study participants was discontinued because of intractable side effects. No difference was found between the two treatment groups in terms of the occurrence of side effects or sedation levels.
Clinical conclusions
Comparable efficacy outcomes were observed with both treatments.
Modelling
No modelling was undertaken.
Measure of benefits used in the economic analysis
Because comparable efficacy outcomes were observed with both treatments, the economic evaluation took the form of a cost-minimisation analysis.
